The first trial will determine the sublingual dose equivalent to 25 mg psilocybin administered orally.
Researchers will examine whether MDMA can offset some of the negative side effects of LSD in a therapeutic setting.
A new study sheds light on cognitive behavioral change mechanisms underlying psychedelic assisted psychotherapy.
Brain scans show that psilocybin modulates claustrum connectivity in brain networks.
A double-blind study reveals that mindfulness meditation practice may amplify the positive effects of psilocybin while reducing the likelihood of a bad trip.
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
With the paradigm shift created by psychedelics, a recent study suggests reconsidering the medical model of mental illness.
Comments from Matthew Johnson of Johns Hopkins provide an update on this research.
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
Researchers are uncovering reasons to think there’s more to DMT than just hallucinations.